Skip to main content
Erschienen in: Endocrine Pathology 3/2016

06.05.2016

The Value of HBME-1 and Claudin-1 Expression Profile in the Distinction of BRAF-Like and RAS-Like Phenotypes in Papillary Thyroid Carcinoma

verfasst von: Hasan Gucer, Pelin Bagci, Recep Bedir, Ibrahim Sehitoglu, Ozgur Mete

Erschienen in: Endocrine Pathology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

This study compared the expression profile of HBME-1 and claudin-1 in 90 papillary thyroid carcinomas (PTCs) with respect to the tumor architecture and invasive growth as reflected in 46 BRAF-like, 31 non-invasive RAS, and 13 invasive RAS-like phenotypes. Individual tumors were given an expression score (max 300) by multiplying the percent positive tumor cells by the intensity score (range 0–3). The higher expression of HBME-1 and claudin-1 distinguished BRAF-like phenotype from RAS-like phenotype. The same correlation was also retained for both markers when comparing BRAF-like phenotype with non-invasive and invasive RAS-like phenotypes. The expression scores and positivity rates for both markers did not yield any statistical difference among BRAF-like PTCs. Except the higher positivity rate of HBME-1, invasive RAS-like tumors were not statistically different than their non-invasive counterparts with respect to the positivity rate of claudin-1 and the expression scores of both markers. A central lymph node dissection or selective lymph node sampling was available in 20 specimens. The absence of claudin-1 expression has not been a feature of lymph node metastasis in this series. Despite the limited number of nodal sampling, BRAF-like phenotype and claudin-1 positivity status have been considered the best determinants of positive predictive value and negative predictive value in the prediction of lymph node metastasis among variables, respectively. Adoption of the simplified architectural classification approach to PTCs showed distinct biomarker expression profile in this series; however, immunohistochemistry for HBME-1 and claudin-1 does not seem to be useful in the distinction of invasive RAS-like PTCs from their non-invasive counterparts. Given the overlapping molecular signatures within the RAS-like phenotype, further studies with additional biomarkers are still needed to identify distinct protein expression signatures of non-invasive RAS-like phenotype as this diagnostic category still remains a surgical diagnosis at this time.
Literatur
1.
Zurück zum Zitat Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159(3):676–90, 2014.CrossRef Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159(3):676–90, 2014.CrossRef
2.
Zurück zum Zitat Mete O, Asa SL, eds. Endocrine Pathology. Cambridge University Press; 2016. Mete O, Asa SL, eds. Endocrine Pathology. Cambridge University Press; 2016.
3.
Zurück zum Zitat Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1):1–133, 2016.CrossRefPubMed Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1):1–133, 2016.CrossRefPubMed
4.
Zurück zum Zitat Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, Hodak SP, Lloyd RV, Maytal G, Mete O, Nikiforova MN, Nosé V, Papotti M, Poller DN, Sadow PM, Tischler AS, Tuttle RM, Wall KB, LiVolsi VA, Randolph GW, Ghossein RA. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016 Apr 14. doi:10.1001/jamaoncol.2016.0386. [Epub ahead of print]. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, Hodak SP, Lloyd RV, Maytal G, Mete O, Nikiforova MN, Nosé V, Papotti M, Poller DN, Sadow PM, Tischler AS, Tuttle RM, Wall KB, LiVolsi VA, Randolph GW, Ghossein RA. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016 Apr 14. doi:10.​1001/​jamaoncol.​2016.​0386. [Epub ahead of print].
5.
Zurück zum Zitat Maletta F, Massa F, Torregrossa L, Duregon E, Casadei GP, Basolo F, Tallini G, Volante M, Nikiforov YE, Papotti M. Cytological features of “non-invasive follicular thyroid neoplasm with papillary-like nuclear features” and their correlation with tumor histology. Hum Pathol. 2016 Apr 13. pii:S0046-8177(16)30033-8. doi: 10.1016/j.humpath.2016.03.014. Maletta F, Massa F, Torregrossa L, Duregon E, Casadei GP, Basolo F, Tallini G, Volante M, Nikiforov YE, Papotti M. Cytological features of “non-invasive follicular thyroid neoplasm with papillary-like nuclear features” and their correlation with tumor histology. Hum Pathol. 2016 Apr 13. pii:S0046-8177(16)30033-8. doi: 10.​1016/​j.​humpath.​2016.​03.​014.
6.
Zurück zum Zitat Singh AB, Sharma A, Dhawan P. Claudin family of proteins and cancer: an overview. J Oncol. 2010:541957, 2010. Singh AB, Sharma A, Dhawan P. Claudin family of proteins and cancer: an overview. J Oncol. 2010:541957, 2010.
8.
Zurück zum Zitat Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 12;6:186, 2006. Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 12;6:186, 2006.
9.
Zurück zum Zitat Zwanziger D, Badziong J, Ting S, Moeller LC, Kurt Werner S, Siebolts U, Wickenhauser C, Dralle H, Fuehrer D. The impact of CLAUDIN-1 on follicular thyroid carcinoma aggressiveness. Endocr Relat Cancer 22(5):819–30, 2015.CrossRefPubMed Zwanziger D, Badziong J, Ting S, Moeller LC, Kurt Werner S, Siebolts U, Wickenhauser C, Dralle H, Fuehrer D. The impact of CLAUDIN-1 on follicular thyroid carcinoma aggressiveness. Endocr Relat Cancer 22(5):819–30, 2015.CrossRefPubMed
10.
Zurück zum Zitat Hucz J, Kowalska M, Jarzab M, Wiench M. Gene expression of metalloproteinase 11, claudin 1 and selected adhesion related genes in papillary thyroid cancer.Endokrynol Pol 57 Suppl A:18–25, 2006. Hucz J, Kowalska M, Jarzab M, Wiench M. Gene expression of metalloproteinase 11, claudin 1 and selected adhesion related genes in papillary thyroid cancer.Endokrynol Pol 57 Suppl A:18–25, 2006.
11.
Zurück zum Zitat Németh J, Németh Z, Tátrai P, Péter I, Somorácz A, Szász AM, Kiss A, Schaff Z. High expression of claudin-1 protein in papillary thyroid tumor and its regional lymph node metastasis. Pathol Oncol Res 16(1):19–27, 2010.CrossRefPubMed Németh J, Németh Z, Tátrai P, Péter I, Somorácz A, Szász AM, Kiss A, Schaff Z. High expression of claudin-1 protein in papillary thyroid tumor and its regional lymph node metastasis. Pathol Oncol Res 16(1):19–27, 2010.CrossRefPubMed
12.
Zurück zum Zitat Abd El Atti RM, Shash LS. Potential diagnostic utility of CD56 and claudin-1 in papillary thyroid carcinoma and solitary follicular thyroid nodules. J Egypt Natl Canc Inst 24(4):175–84, 2012.CrossRefPubMed Abd El Atti RM, Shash LS. Potential diagnostic utility of CD56 and claudin-1 in papillary thyroid carcinoma and solitary follicular thyroid nodules. J Egypt Natl Canc Inst 24(4):175–84, 2012.CrossRefPubMed
13.
Zurück zum Zitat Ma H, Xu S, Yan J, Zhang C, Qin S, Wang X, Li N. The value of tumor markers in the diagnosis of papillary thyroid carcinoma alone and in combination. Pol J Pathol 65(3):202–9, 2014.CrossRefPubMed Ma H, Xu S, Yan J, Zhang C, Qin S, Wang X, Li N. The value of tumor markers in the diagnosis of papillary thyroid carcinoma alone and in combination. Pol J Pathol 65(3):202–9, 2014.CrossRefPubMed
14.
Zurück zum Zitat Tzelepi VN, Tsamandas AC, Vlotinou HD, Vagianos CE, Scopa CD. Tight junctions in thyroid carcinogenesis: diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid neoplasms. Mod Pathol 21(1):22–30, 2008.CrossRefPubMed Tzelepi VN, Tsamandas AC, Vlotinou HD, Vagianos CE, Scopa CD. Tight junctions in thyroid carcinogenesis: diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid neoplasms. Mod Pathol 21(1):22–30, 2008.CrossRefPubMed
15.
Zurück zum Zitat Chui MH, Cassol CA, Asa SL, Mete O. Follicular epithelial dysplasia of the thyroid: morphological and immunohistochemical characterization of a putative preneoplastic lesion to papillary thyroid carcinoma in chronic lymphocytic thyroiditis. Virchows Arch 462(5):557–63, 2013.CrossRefPubMed Chui MH, Cassol CA, Asa SL, Mete O. Follicular epithelial dysplasia of the thyroid: morphological and immunohistochemical characterization of a putative preneoplastic lesion to papillary thyroid carcinoma in chronic lymphocytic thyroiditis. Virchows Arch 462(5):557–63, 2013.CrossRefPubMed
16.
Zurück zum Zitat Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S, Ozdamar SO. Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol 21:80–89, 2010.CrossRefPubMed Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S, Ozdamar SO. Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol 21:80–89, 2010.CrossRefPubMed
17.
Zurück zum Zitat Fischer S, Asa SL. Application of immunohistochemistry to thyroid neoplasms. Arch Pathol Lab Med 132:359–372, 2008.PubMed Fischer S, Asa SL. Application of immunohistochemistry to thyroid neoplasms. Arch Pathol Lab Med 132:359–372, 2008.PubMed
18.
Zurück zum Zitat Nga ME, Lim GS, Soh CH, Kumarasinghe MP. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma. Diagn Cytopathol 36:550–556, 2008.CrossRefPubMed Nga ME, Lim GS, Soh CH, Kumarasinghe MP. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma. Diagn Cytopathol 36:550–556, 2008.CrossRefPubMed
19.
Zurück zum Zitat Mete O, Asa SL. Pitfalls in the diagnosis of follicular epithelial proliferations of the thyroid. Adv Anat Pathol 19:363–373, 2012.CrossRefPubMed Mete O, Asa SL. Pitfalls in the diagnosis of follicular epithelial proliferations of the thyroid. Adv Anat Pathol 19:363–373, 2012.CrossRefPubMed
20.
Zurück zum Zitat Fluge Ø, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE. Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid 16(2):161–75, 2006.CrossRefPubMed Fluge Ø, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE. Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid 16(2):161–75, 2006.CrossRefPubMed
21.
Zurück zum Zitat Ma H, Yan J, Zhang C, Qin S, Qin L, Liu L, Wang X, Li N. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto’s thyroiditis. Int J Clin Exp Pathol 7(11):7999–8007, 2014.PubMedPubMedCentral Ma H, Yan J, Zhang C, Qin S, Qin L, Liu L, Wang X, Li N. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto’s thyroiditis. Int J Clin Exp Pathol 7(11):7999–8007, 2014.PubMedPubMedCentral
22.
Zurück zum Zitat Onder S, Ozturk Sari S, Yegen G, Sormaz IC, Yilmaz I, Poyrazoglu S, Sanlı Y, Giles Senyurek Y, Kapran Y, Mete O. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF(V600E) Harboring Pediatric Papillary Thyroid Carcinomas. Endocr Pathol 27(2):153–161, 2016. Onder S, Ozturk Sari S, Yegen G, Sormaz IC, Yilmaz I, Poyrazoglu S, Sanlı Y, Giles Senyurek Y, Kapran Y, Mete O. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF(V600E) Harboring Pediatric Papillary Thyroid Carcinomas. Endocr Pathol 27(2):153–161, 2016.
23.
Zurück zum Zitat Jakubowski M, Hunt JL. BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns. Am J Surg Pathol 33(11):1590–3, 2009.CrossRefPubMed Jakubowski M, Hunt JL. BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns. Am J Surg Pathol 33(11):1590–3, 2009.CrossRefPubMed
24.
Zurück zum Zitat Asa SL, Giordano TJ, LiVolsi VA. Implications of the TCGA genomic characterization of papillary thyroid carcinoma for thyroid pathology: does follicular variant papillary thyroid carcinoma exist? Thyroid 25(1):1–2, 2015.CrossRefPubMed Asa SL, Giordano TJ, LiVolsi VA. Implications of the TCGA genomic characterization of papillary thyroid carcinoma for thyroid pathology: does follicular variant papillary thyroid carcinoma exist? Thyroid 25(1):1–2, 2015.CrossRefPubMed
25.
Zurück zum Zitat Khoo ML, Beasley NJ, Ezzat S, Freeman JL, Asa SL. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab 87:1814–1818, 2002.CrossRefPubMed Khoo ML, Beasley NJ, Ezzat S, Freeman JL, Asa SL. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab 87:1814–1818, 2002.CrossRefPubMed
26.
Zurück zum Zitat Khoo ML, Freeman JL, Witterick IJ, Irish JC, Rotstein LE, Gullane PJ, Asa SL. Underexpression of p27/Kip in thyroid papillary microcarcinomas with gross metastatic disease. Arch Otolaryngol Head Neck Surg 128:253–257, 2002.CrossRefPubMed Khoo ML, Freeman JL, Witterick IJ, Irish JC, Rotstein LE, Gullane PJ, Asa SL. Underexpression of p27/Kip in thyroid papillary microcarcinomas with gross metastatic disease. Arch Otolaryngol Head Neck Surg 128:253–257, 2002.CrossRefPubMed
27.
Zurück zum Zitat Karlidag T, Cobanoglu B, Keles E, Alpay HC, Ozercan I, Kaygusuz I, Yalcin S, Sakallioglu O. Expression of Bax, p53, and p27/kip in patients with papillary thyroid carcinoma with or without cervical nodal metastasis. Am J Otolaryngol 28:31–36, 2007.CrossRefPubMed Karlidag T, Cobanoglu B, Keles E, Alpay HC, Ozercan I, Kaygusuz I, Yalcin S, Sakallioglu O. Expression of Bax, p53, and p27/kip in patients with papillary thyroid carcinoma with or without cervical nodal metastasis. Am J Otolaryngol 28:31–36, 2007.CrossRefPubMed
28.
Zurück zum Zitat Pesutić-Pisac V, Punda A, Gluncić I, Bedeković V, Pranić-Kragić A, Kunac N. Cyclin D1 and p27 expression as prognostic factor in papillary carcinoma of thyroid: association with clinicopathological parameters. Croat Med J 49:643–649, 2008.CrossRefPubMedPubMedCentral Pesutić-Pisac V, Punda A, Gluncić I, Bedeković V, Pranić-Kragić A, Kunac N. Cyclin D1 and p27 expression as prognostic factor in papillary carcinoma of thyroid: association with clinicopathological parameters. Croat Med J 49:643–649, 2008.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Cheng S, Serra S, Mercado M, Ezzat S, Asa SL. A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clin Cancer Res 17:2385–2394, 2011.CrossRefPubMed Cheng S, Serra S, Mercado M, Ezzat S, Asa SL. A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clin Cancer Res 17:2385–2394, 2011.CrossRefPubMed
Metadaten
Titel
The Value of HBME-1 and Claudin-1 Expression Profile in the Distinction of BRAF-Like and RAS-Like Phenotypes in Papillary Thyroid Carcinoma
verfasst von
Hasan Gucer
Pelin Bagci
Recep Bedir
Ibrahim Sehitoglu
Ozgur Mete
Publikationsdatum
06.05.2016
Verlag
Springer US
Erschienen in
Endocrine Pathology / Ausgabe 3/2016
Print ISSN: 1046-3976
Elektronische ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-016-9433-8

Weitere Artikel der Ausgabe 3/2016

Endocrine Pathology 3/2016 Zur Ausgabe

Neu im Fachgebiet Pathologie